Company description

Oncodesign Services is a biotechnology CRO headquartered in Dijon, France, providing integrated drug discovery and preclinical research services to pharmaceutical and biotechnology companies. Founded in 1995 as part of the broader Oncodesign group, the company was later established as a standalone entity focused on services following a strategic separation of business units.

The company supports drug development programmes from early target identification through to IND-enabling studies, helping clients progress candidates towards clinical development. Its expertise lies in translational pharmacology, where scientific data is generated and interpreted to support key preclinical decisions and improve the likelihood of clinical success.

Oncodesign Services specialises in high-value therapeutic areas including oncology, immuno-oncology, inflammation, autoimmune diseases and infectious diseases. It has developed strong capabilities in advanced areas such as targeted radiotherapy and radiopharmaceutical research, supporting next-generation therapeutic approaches.

The company operates internationally with facilities in Europe and North America and employs a multidisciplinary team of scientists with expertise in pharmacology, medicinal chemistry, imaging and bioanalysis. Its infrastructure includes AAALAC-accredited research facilities and advanced imaging platforms to support translational studies.

With over two decades of experience, Oncodesign Services positions itself as a strategic partner for biotech and pharma companies, particularly in the critical transition from discovery to clinical development.

Key products and services

Integrated drug discovery platform

• Target identification and validation
• Hit discovery and lead optimisation
• End-to-end discovery support through IND filing

Translational pharmacology

• In vitro and in vivo pharmacology studies
• Proof-of-concept (PoC) studies in oncology and inflammation
• Mechanism-of-action and biomarker studies

DMPK and bioanalysis

• Drug metabolism and pharmacokinetics (DMPK)
• Bioanalytical method development
• Regulatory and non-GLP studies

Pharmaco-imaging and radiopharmaceutical services

• Molecular imaging and biodistribution studies
• Target engagement and efficacy assessment
• Radiopharmaceutical and targeted radiotherapy support

Preclinical development services

• IND-enabling studies
• Safety and efficacy evaluation
• Microbiome and immunology research

Therapeutic expertise

• Oncology and immuno-oncology
• Inflammation and autoimmune diseases
• Infectious diseases and radiotherapy applications

By combining deep expertise in translational pharmacology with integrated drug discovery and advanced imaging capabilities, Oncodesign Services supports pharmaceutical and biotechnology companies in advancing complex therapeutic programmes towards the clinic. Its focus on oncology, radiopharmaceuticals and high-value disease areas positions the company as a specialised CRO partner for early-stage drug development.